Oragenics moves ahead with SARS-CoV-2 vaccine

By The Science Advisory Board staff writers

October 6, 2020 -- Oragenics is moving ahead with its SARS-CoV-2 vaccine called Terra CoV-2 with the support of the U.S. Food and Drug Administration (FDA).

The company plans to file an investigational new drug (IND) application for Terra CoV-2 by the end of the first quarter of 2021 and to begin a phase I study in the second quarter, it said. The FDA has requested that Oragenics include additional preclinical animal data in its IND, according to the firm.

Oragenics acquired a nonexclusive license for Terra CoV-2 from the U.S. National Institutes of Health (NIH) in March.


Copyright © 2020 scienceboard.net
 


MemberID or email address:

Password:
Forgot your password?